The neurofilament heavy chain (NfHSMI35) in the cerebrospinal fluid diagnosis of Alzheimer's disease
Standard
The neurofilament heavy chain (NfHSMI35) in the cerebrospinal fluid diagnosis of Alzheimer's disease. / Brettschneider, Johannes; Petzold, Axel; Schöttle, Daniel; Claus, Annett; Riepe, Matthias; Tumani, Hayrettin.
in: Dementia and Geriatric Cognitive Disorders, Jahrgang 21, Nr. 5-6, 05.2006, S. 291-295.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - The neurofilament heavy chain (NfHSMI35) in the cerebrospinal fluid diagnosis of Alzheimer's disease
AU - Brettschneider, Johannes
AU - Petzold, Axel
AU - Schöttle, Daniel
AU - Claus, Annett
AU - Riepe, Matthias
AU - Tumani, Hayrettin
N1 - Copyright: Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2006/5
Y1 - 2006/5
N2 - Background/Aims: Attempting to improve the cerebrospinal fluid (CSF) diagnosis of Alzheimer's disease (AD), the neurofilament heavy chain isoform, NfHSMI35 was compared to other CSF markers [total tau, phospho-tau, amyloid beta 1-42 (Aβ42), the ratio of amyloid beta fragments Aβ42/Aβ40 (Aβ ratio)]. Methods: CSF levels were determined in patients with AD (n = 109), mild cognitive impairment (MCI, n = 25), frontotemporal dementia (n = 15), vascular dementia (VD, n = 41), and controls (n = 58). Results: CSF NfHSMI35 was elevated in AD and VD as compared to controls (p < 0.05). Total tau was higher in AD as compared to controls (p < 0.05). CSF phospho-tau was elevated in AD as compared to controls and VD (p < 0.05 each). CSF Aβ42 and Aβ ratios in AD were lower than in MCI and controls (p < 0.05 each). Conclusion: The diagnostic potential of NfHSMI35 is not superior to that of other CSF markers.
AB - Background/Aims: Attempting to improve the cerebrospinal fluid (CSF) diagnosis of Alzheimer's disease (AD), the neurofilament heavy chain isoform, NfHSMI35 was compared to other CSF markers [total tau, phospho-tau, amyloid beta 1-42 (Aβ42), the ratio of amyloid beta fragments Aβ42/Aβ40 (Aβ ratio)]. Methods: CSF levels were determined in patients with AD (n = 109), mild cognitive impairment (MCI, n = 25), frontotemporal dementia (n = 15), vascular dementia (VD, n = 41), and controls (n = 58). Results: CSF NfHSMI35 was elevated in AD and VD as compared to controls (p < 0.05). Total tau was higher in AD as compared to controls (p < 0.05). CSF phospho-tau was elevated in AD as compared to controls and VD (p < 0.05 each). CSF Aβ42 and Aβ ratios in AD were lower than in MCI and controls (p < 0.05 each). Conclusion: The diagnostic potential of NfHSMI35 is not superior to that of other CSF markers.
KW - Alzheimer's disease
KW - Cerebrospinal fluid
KW - Markers, diagnostic
KW - NfH
UR - http://www.scopus.com/inward/record.url?scp=33646707066&partnerID=8YFLogxK
U2 - 10.1159/000091436
DO - 10.1159/000091436
M3 - SCORING: Journal article
C2 - 16484807
AN - SCOPUS:33646707066
VL - 21
SP - 291
EP - 295
JO - DEMENT GERIATR COGN
JF - DEMENT GERIATR COGN
SN - 1420-8008
IS - 5-6
ER -